GlassScriptPhysician profile
Brittani J Thomas
NPI 1972940179
$7,388.37
in general payments reported to CMS, 2019-2025
40 companies · $2,141 in 2025
The $2,141 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79.43 · 2020: $418 · 2021: $1,011 · 2022: $764 · 2023: $1,444 · 2024: $1,531 · 2025: $2,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,807 · Long Term Medical Supply Or Device Loan: $1,097 · Education: $212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,806.64 |
| Long Term Medical Supply Or Device Loan | $1,096.70 |
| Education | $212.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,124.92 | 2020-2025 | |
| Amgen INC. | $499.57 | 2020-2023 | Vectibix, Nplate, Xgeva |
| Genentech USA, INC. | $415.20 | 2021-2025 | Venclexta, Phesgo, Perjeta |
| Astrazeneca Pharmaceuticals LP | $390.81 | 2020-2025 | Imfinzi, Enhertu, Lynparza |
| Celgene Corporation | $348.32 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Gilead Sciences, INC. | $283.12 | 2021-2025 | Trodelvy |
| Pfizer INC. | $279.24 | 2020-2025 | |
| Seagen INC. | $272.01 | 2019-2023 | Tukysa |
| Lilly USA, LLC | $271.26 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Astellas Pharma US INC | $234.89 | 2020-2025 | Xospata, Padcev |
| Eisai INC. | $198.15 | 2020-2025 | |
| Merck Sharp & Dohme LLC | $178.22 | 2020-2024 | Keytruda, Lynparza |
| Sirtex Medical INC | $148.10 | 2022 | |
| Daiichi Sankyo INC. | $147.68 | 2021-2024 | Enhertu, Vanflyta |
| Glaxosmithkline, LLC. | $132.58 | 2022-2025 | Ojjaara, Blenrep |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $126.58 | 2021-2024 | Iclusig, Gammagard |
| Abbvie INC. | $120.84 | 2022-2025 | |
| Janssen Biotech, INC. | $116.56 | 2022-2025 | Erleada, Tremfya, Darzalex |
| Servier Pharmaceuticals LLC | $104.98 | 2022-2025 | |
| Array Biopharma INC | $101.88 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Puma Biotechnology, INC. | $91.52 | 2020-2024 | |
| E.R. Squibb & Sons, L.L.C. | $87.49 | 2020-2024 | Opdivo |
| Genzyme Corporation | $79.84 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $73.99 | 2023-2025 | Orgovyx |
| Stemline Therapeutics INC. | $72.27 | 2023-2025 | Orserdu |
| Agios Pharmaceuticals, INC. | $62.99 | 2020-2024 | |
| Incyte Corporation | $60.44 | 2024-2025 | Zynyz, Jakafi |
| Foundation Medicine, INC. | $52.91 | 2019-2020 | |
| Beigene USA, INC. | $45.27 | 2023-2025 | Brukinsa |
| Tersera Therapeutics LLC | $44.47 | 2024-2025 | Zoladex |
| Mirati Therapeutics, INC. | $37.58 | 2023 | Krazati |
| Sobi, INC | $33.54 | 2022-2024 | |
| Acrotech Biopharma INC. | $23.63 | 2023 | Beleodaq |
| Karyopharm Therapeutics INC. | $20.84 | 2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $19.90 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $19.28 | 2019 | |
| Kite Pharma, INC. | $18.44 | 2022 | |
| Deciphera Pharmaceuticals INC. | $18.07 | 2024 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $17.36 | 2024 | |
| Emd Serono, INC. | $13.63 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittani Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.